SEARCH VEGSOURCE:

 

 

Follow Ups | Post Followup | Back to Discussion Board | VegSource
See spam or
inappropriate posts?
Please let us know.
  




From: TSS ()
Subject: Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases
Date: February 28, 2007 at 9:32 am PST

Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases
Claire Larramendy-Gozalo1, Agnès Barret1, Estelle Daudigeos1, Emilie Mathieu1, Lucie Antonangeli1, Cécile Riffet2, Emmanuel Petit3, Dulce Papy-Garcia2, Denis Barritault3, Paul Brown1 and Jean-Philippe Deslys1

1 CEA, IMETI/SEPIA, 18 route du Panorama, BP6, 92265 Fontenay-aux-Roses cedex, France
2 Laboratoire CRRET, CNRS FRE24-12, Université Paris XII-Val de Marne, Avenue du Général de Gaulle, 94010 Créteil, France
3 OTR3 Sarl, 4 Rue Française, 75001 Paris, France


Correspondence
Jean-Philippe Deslys
jpdeslys@cea.fr

Sulfated polyanions, including pentosan polysulfate (PPS) and heparan mimetics, number among the most effective drugs that have been used in experimental models of prion disease and are presumed to act in competition with endogenous heparan sulfate proteoglycans as co-receptors for prion protein (PrP) on the cell surface. PPS has been shown to prolong the survival of animals after intracerebral perfusion and is in limited use for the experimental treatment of human transmissible spongiform encephalopathies (TSEs). Here, PPS is compared with CR36, a new heparan mimetic. Ex vivo, CR36 was more efficient than PPS in reducing PrPres in scrapie-infected cell cultures and showed long-lasting activity. In vivo, CR36 showed none of the acute toxicity observed with PPS and reduced PrPres accumulation in spleens, but had only a marginal effect on the survival time of mice infected with bovine spongiform encephalopathy. In contrast, mice treated with PPS that survived the initial toxic mortality had no detectable PrPres in the spleens and lived 185 days longer than controls (+55 %). These results show, once again, that anti-TSE drugs cannot be encouraged for human therapeutic trials solely on the basis of in vitro or ex vivo observations, but must first be subjected to in vivo animal studies.

http://vir.sgmjournals.org/cgi/content/abstract/88/3/1062?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=prion&searchid=1&FIRSTINDEX=0&volume=88&issue=3&resourcetype=HWCIT

TSS




Follow Ups:



Post a Followup

Name:
E-mail: (optional)
Subject:

Comments:

Optional Link URL:
Link Title:
Optional Image URL: